SCHEMBL6795422

SCHEMBL6795422

Cc1ccc(-c2ccccc2C(=O)Nc2ccc(N(C=O)CCc3ccccn3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SMO Q99835 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
CHRNB2 P17787 2/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNA4 P43681 2/20 0.41
KMT2A Q03164 1/20 0.41
CYP3A4 P08684 1/20 0.41
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792296 0.87 CA12 (0.42) HTTLMNAKDM4ESMONPC1
SCHEMBL6794600 0.86 L3MBTL1 (0.44) HTTL3MBTL1LMNAKDM4ESMO
SCHEMBL6645984 0.83 KCNH2 (0.44) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6644523 0.83 KDM4E (0.41) HTTL3MBTL1LMNAKDM4ENPC1
SCHEMBL6644991 0.83 CTNNB1 (0.41) HTTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL6489397 0.82 L3MBTL1 (0.41) HTTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL6500051 0.82 L3MBTL1 (0.41) HTTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL6489838 0.81 L3MBTL1 (0.40) HTTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL6799630 0.81 SMO (0.42) HTTL3MBTL1LMNAKDM4ESMO
SCHEMBL6501907 0.81 L3MBTL1 (0.40) HTTL3MBTL1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 HTT 2566/4885L3MBTL1 1793/4885LMNA 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.